Embodiments of the disclosure relate to tetrahydropyrazolopyrimidine compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis
本公开的实施例涉及四氢
吡唑并
嘧啶化合物,其作为Toll样受体7和/或8的拮抗剂或
抑制剂,并且它们在制备有效的药物组合物方面的使用,用于治疗系统性红斑狼疮(SLE)和狼疮性肾炎。